David A. Siegel Obs Eva Sa Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$1.89 - $2.55 $43,281 - $58,394	-22,900 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.46 - $6.15 $6,150 - $15,375	2,500 Added 12.25%	22,900 $57,000
Q2 2020 Aug 14, 2020	SELL	$2.01 - $5.95 $18,290 - $54,145	-9,100 Reduced 30.85%	20,400 $120,000
Q1 2020 May 15, 2020	BUY	$1.87 - $4.47 $36,091 - $86,271	19,300 Added 189.22%	29,500 $71,000
Q4 2019 Feb 14, 2020	BUY	$2.48 - $8.1 $25,296 - $82,620	10,200 New	10,200 $39,000

88K

Ticker OBSV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,499,200
Description
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.